Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05687890 | A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | PHASE2 | ACTIVE NOT_RECRUITING | 255 | — | — | May 23, 2023 | Apr 1, 2025 | Jan 7, 2025 | 1 | China |
Change from baseline at Week 12 in urine albumin creatinine ratio (UACR) in Cohort 1
Change from baseline at Week 12 in urine protein creatinine ratio (UPCR) in Cohort 2
| Arm | Type | Description |
|---|---|---|
| SC0062 low dose group | EXPERIMENTAL | Subjects will take two capsules daily for 24 weeks during the treatment period |
| SC0062 medium dose group | EXPERIMENTAL | Subjects will take two capsules daily for 24 weeks during the treatment period |
| SC0062 high dose group | EXPERIMENTAL | Subjects will take two capsules daily for 24 weeks during the treatment period |
| Placebo of SC0062 group | PLACEBO_COMPARATOR | Subjects will take two capsules daily for 24 weeks during the treatment period |
| Name | Type | Description |
|---|---|---|
| Placebo of SC0062 | DRUG | Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period |
| SC0062 low dose | DRUG | Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period |
| SC0062 medium dose | DRUG | Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period |
| SC0062 high dose | DRUG | Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period |
Inclusion Criteria: 1. Sign the informed consent voluntarily, and fully understand and comply with the relevant procedures of the test; 2. Age of ≥ 18 years old, gender is not limited; 3. Patients with chronic kidney disease (CKD) stage G1\~G3 with albuminuria, requirements: 1. eGFR ≥ 30 mL/min...